Verastem股价飙升,其KRAS抑制剂在肺癌治疗中展现强劲疗效

老虎资讯综合
Aug 14, 2025

Verastem公司(纳斯达克股票代码:VSTM)夜盘上涨16%,此前该公司宣布了其KRAS G12D抑制剂在晚期非小细胞肺癌患者中的积极更新数据。

这家生物制药公司报告称,其合作伙伴劲方医药(GenFleet Therapeutics)在中国进行的1/2期研究显示,在推荐的2期剂量下,药物GFH375(在中国以外称为VS-7375)的客观缓解率(ORR)达到68.8%。在所有剂量水平下,该药物在携带KRAS G12D突变的晚期非小细胞肺癌患者中均显示出57.7%的客观缓解率。

Verastem Oncology总裁兼首席执行官丹·彼得森(Dan Paterson)表示:“晚期肺癌患者的应答率显著提高,在推荐的2期剂量下达到68.8%的客观缓解率,在所有剂量水平下达到57.7%的客观缓解率,这一结果令人印象深刻,并持续支持VS-7375在晚期肺癌以及其他晚期KRAS G12D实体瘤中的开发潜力和前景。”

该研究共纳入142名患者,其中28名为晚期非小细胞肺癌患者。这些肺癌患者中的大多数(64.3%)先前至少接受过两种全身性疗法治疗,且几乎所有人(96.4%)都接受过抗PD-1/PD-L1疗法治疗。

治疗相关不良事件(TRAE)的严重程度主要为1级或2级(轻度或中度),最常见的是腹泻、呕吐和恶心。研究中未报告与治疗相关的死亡病例。


Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10